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Abstract: The mechanism whereby agonist occupancy
of muscarinic cholinergic receptors elicits an increased
tyrosine phosphorylation of focal adhesion kinase (FAK)
and paxillin has been examined. Addition of oxotremo-
rine-M to SH-SY5Y neuroblastoma cells resulted in rapid
increases in the phosphorylation of FAK (t112 = 2 mm)and
paxillin that were independent of integrin—extracellular
matrix interactions, cell attachment, and the production
of phosphoinositide-derived second messengers. In con-
trast, the increased tyrosine phosphorylations of FAK and
paxillin were inhibited by inclusion of either cytochalasin
D or mevastatin, agents that disrupt the cytoskeleton.
Furthermore, phosphorylation of FAK and paxillin could
be prevented by addition of either wortmannin or LY-
294002, under conditions in which the synthesis of phos-
phatidylinositol 4-phosphate was markedly attenuated.
These results indicate that muscarinic receptor-mediated
increases in the tyrosine phosphorylation of FAK and pax-
illin in SH-SY5Y neuroblastoma cells depend on both the
maintenance of an actin cytoskeleton and the ability
of these cells to synthesize phosphoinositides. Key
Words: Actin polymerization—Phosphatidylinositol 4-
phosphate— Cytochalasin — LY-294002— Mevastatin —
Wortmannin.
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Focal adhesion kinase (FAK) is a 125-kDa cyto-
plasmic protein tyrosine kinase originally identified in
v-src-transformed chicken embryo fibroblasts (Schal-
ler et al., 1992). Integrin-mediated attachment of fi-
broblasts to extracellular matrix (ECM) proteins in-
duces the tyrosine phosphorylation of FAK, increased
kinase activity, and localization to focal adhesions
(Burridge et al., 1992; Guan and Shalloway, 1992;
Hanks et al., 1992; Kornberg et al., 1992). Several
putative downstream substrates for FAK have been
identified, one of which is the cytoskeletal protein
paxillin (Bellis et al., 1995; Schaller and Parsons,
1995). Thus, FAK has been implicated as a potential
regulator of integrin-mediated signal transduction and
cytoskeletal assembly at sitesof developing focal adhe-
sions. Recently, FAK has been identified in neural tis-
sue both in vitro (Zhang et al., 1994; Derkinderen et
al., 1996) and in vivo (Grant et al., 1995). Further-
more, both FAK and paxillin have been implicated in
a signal transduction pathway linked to neurite out-
growth (Bianchi et al., 1995; Maroney et al., 1995;
Leventhal and Feldman, 1996; Leventhal et al., 1997).
In addition to integrin activation, the tyrosine phos-
phorylation of FAK is enhanced in fibroblasts in re-
sponse to multiple stimuli, including transformation
by retroviral oncogenes (Guan and Shalloway, 1992),
growth factors for receptor tyrosine kinases (Rankin et
al., 1996), bioactive lipids (Seufferlein and Rozengurt,
1994a,b), and phorbol esters (Sinnett-Smith et al.,
1993). Furthermore, agonist occupancy of receptors
that couple to phosphoinositide hydrolysis has also
been demonstrated to elicit an increase in the tyrosine
phosphorylation of FAK, although the mechanism
whereby this occurs has yet to be defined (Sinnett-
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Smith et al., 1993; Leeb-Lundberg et al., 1994; Rankin
et al., 1994).
Recently it was reported that activation of musca-
rinic cholinergic receptors (mAChRs) present on SH-
SY5Y neuroblastoma cells resulted in morphological
changes characteristic of neurite outgrowth (Rösner et
al., 1995). Given that (a) mAChRs on these cells are
known to couple to phosphoinositide hydrolysis
(Fisher et al., 1994; Slowiejko et al., 1996) and (b)
the presence of both FAK and paxillin has been docu-
mented in SH-SY5Y cells (Leventhal and Feldman,
1996; Leventhal et al., 1997), the observations of
Rosner et al. (1995) prompted us to determine whether
the activation of mAChRs in SH-SY5Y cells resulted
in an increased tyrosine phosphorylation of FAK and,
if so, the mechanism by which this occurs.
The results indicate that, on agonist occupancy of
mAChRs in SH-SY5Y cells, there is a rapid increase
in the tyrosine phosphorylation of FAK and paxillin.
This appears to occur independently of the production
of phosphoinositide-derived second messengers but is
absolutely dependent on the presence of an intact actin
cytoskeleton. Agonist-stimulated tyrosine phosphory-
lation of both FAK and paxillin was also blocked by
pretreatment of the cells with either wortmannin or
LY-294002 [2- (4-morpholinyl ) -8-phenyl-4H- 1-ben-
zopyran-4-one 1~under conditions in which the synthe-
sis of phosphatidylinositol (PT) 4-phosphate [P1(4) F]
was markedly attenuated. The data suggest that the
maintenance of an actin microfilament network and
the continuous ability of these cells to synthesize phos-
phoinositides are prerequisites for the tyrosine phos-
phorylation of FAK and paxillin that occurs in re-
sponse to mAChR activation. A preliminary account
of part of this study has previously been reported
(Linseman et al., 1997).
MATERIALS AND METHODS
Materials
Cytochalasin D, thapsigargin, phorbol 12-myristate 13-
acetate (PMA), Ro 31-8220, ML-7, arachidonyl trifluoro-
methyl ketone (AACOCF3), quinacrine, 1-oleoyl-2-acetyl-
sn-glycerol, andLY-294002 were obtainedfrom Calbiochem
(San Diego, CA, U.S.A.). Atropine, pilocarpine, mevastatin,
mevalonic acid lactone, retinoic acid, and wortmannin were
from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Oxo-
tremorine-M [Oxo-M; N,N,N-trimethyl-4-( 2-oxo- 1 -pyrroli-
dinyl)-2-butyn- 1 -ammonium iodide] was purchased from
Research Biochemicals International (Natick, MA, U.S.A.).
Recombinant C3 exoenzyme was a kind gift from Dr. Carol
Williams (Guthrie Research Institute, Sayre, PA, U.S.A.) or
was purchased from Upstate Biotechnology (Lake Placid,
NY, U.S.A.). All other chemicals were of reagent grade.
myo- [2-
3H] Inositol, [32P]orthophosphoric acid, [N-methyl-
3H] scopolamine methyl chloride ([3H I NMS), reagents for
enhanced chemiluminescence (ECL), and peroxidase-conju-
gated sheep anti-mouseIgG were purchased from Amersham
Corp. (Arlington Heights, IL, U.S.A.). [32P]NAD was ob-
tained from New England Nuclear (Boston, MA, U.S.A.).
Monoclonal antibodies to phosphotyrosine and paxillin and
a polyclonal antibody to PT 3-kinase were from Upstate Bio-
technology or Transduction Laboratories (Lexington, KY,
U.S.A.). Polyclonal antibody to the active forms of ERK1
and ERK2 was purchased from Promega (Madison, WI,
U.S.A.). Polyclonal antibody to FAK, peroxidase-conju-
gated goat anti-rabbit IgG, and agarose-conjugated protein
A/G were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, U.S.A.). Tissue culture supplies were purchased
from Corning Glass Works (Corning, NY, U.S.A.) and Sar-
stedt (Newton, NC, U.S.A.). Dulbecco’s modified Eagle’s
medium (DMEM) andfetal calf serum (FCS) were obtained
from GIBCO (Grand Island, NY, U.S.A.) and BioWhittaker
(Walkersville,MD, U.S.A.), respectively. Human SH-SY5Y
neuroblastoma cells were obtained from Dr. June Biedler
(Sloan-Kettering Institute, New York, NY, U.S.A.).
Cell culture conditions
Human SH-SY5Y neuroblastomacells (passages 68—78)
were routinely grown in 75-cm2 tissue culture flasks con-
taining 20 ml of DMEM supplemented with 10% FCS. Cells
were grown for 7—14 days at 37°Cin a humidified atmo-
sphere consisting of 90% air and 10% CO
2. Cells were re-
trieved from the flasks by incubation in a modified Pucks
D1 solution (Honegger andRichelson, 1976). In experiments
using attached cells, the cells were subcultured into 35-mm-
diameter, six-well culture plates (Becton Dickinson Lab-
ware, Lincoln Park, NJ, U.S.A.) for 2—4 days before treat-
ment. In experiments using differentiated cells, SH-SY5Y
cells were grown in the presence of 10 ,uM retinoic acid for
6 days before treatment, as described by Rosner et al.
(1995). All experiments were performed on cells that had
reached confluency.
Treatment conditions and immunoprecipitations
Following removal of the plating medium, confluent 35-
mm-diameter cultures of SH-SY5Y cells were washed once
with 2 ml of prewarmed (37°C)treatment buffercontaining
138 mM NaC1, 6 mM KC1, 1 mM MgCl2, 1 mM CaC12, 1
mM Na2HPO4, 5 mM NaHCO3, 5.5 mM glucose, and 20
mMHEPES (pH 7.4) (Offermanns et al., 1993) and allowed
to equilibrate in the incubator in 1 ml of treatment buffer
(withor without appropriate pretreatment) for 30 mm. Cells
were then stimulated by addition of agonist to the pretreat-
ment solution and returned to the incubator for the appro-
pnate duration. Following agonist exposure, the treatment
buffer was removed, and cells were rinsed once with 2 ml
of ice-cold phosphate-buffered saline (PBS; pH 7.4). Cells
were then incubatedon ice and scraped into lysis buffer (200
~i1per well) containing 20 mM HEPES (pH 7.4), 1% Triton
X-100, 50 mM NaC1, 1 mM EGTA, 5 mM /3-glycerophos-
phate, 30 mM sodium pyrophosphate, 100 ~iMsodium ortho-
vanadate, 1 mM phenylmethylsulfonyl fluoride, 10 ~ig/ml
aprotinin, and 10 ~ig/ml leupeptin (Wahl et al., 1988). Cell
debris was removed by centrifugation at 12,000 g for 5 mm
at 4°C,and the protein concentration of the supernatant was
determined using a commercially available protein assay kit
(Pierce Chemical Co., Rockford, IL, U.S.A.). Aliquots (200
~tg) of detergent-soluble cellular protein were transferred to
tubes containing 1 ~.tgof either anti-FAK polyclonal antibody
or anti-paxillin monoclonal antibody (final volume, 200 iiI)
and incubated at 4°Cfor 16—20 h with continuous mixing.
Protein A/G-agarose (20 /21) was added for an additional 4
h with mixing. Immune complexes were pelleted by centrifu-
gation and washed three times with ice-cold lysis buffer.
Thefinal agarose pellet was resuspended in an equal volume
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of 2x sodium dodecyl sulfate (SDS) —polyacrylamide gel
electrophoresis (PAGE) sample buffer, boiled for 5 mm,
and electrophoresed through 10% polyacrylamide gels
(Laemmli, 1970). Proteins were transferred to polyvinyli-
dene difluoride (PVDF) membranes (Millipore Corp., Bed-
ford, MA, U.S.A.) and processed for immunoblot analysis.
Experiments using SH-SY5Y cells maintained in suspension
were performed following detachment of the cells in D1
solution. Thecells were then washed in prewarmed treatment
buffer, resuspended in 5-ml aliquots of treatment buffer
(with or without agonist), and incubated in a 37°Cshaking
water bath for 10 mm. Samples were agitated every 5 mm
to minimize cell aggregation. Following agonist exposure,
20 ml of ice-cold treatment buffer was added, and the sam-
ples were immediately placed on ice. Cells were pelleted at
4°Cby centrifugation at 1,000 g for 5 mm. Following aspira-
tion of the supernatant, the cell pellet was homogenized on
ice in 1 ml of lysis buffer by 10 strokes with a glass/glass
homogenizer. Cell debris was removed by centrifugation,
and immunoprecipitation of either FAK or paxillin was car-
ried out on the supernatant as described above.
Immunoblot analysis
Nonspecific binding sites were blocked in PBS (pH 7.4)
containing 0.1% Tween 20 (PBS-T) and 1% bovine serum
albumin for 1 h at room temperature. Primary antibodies
were diluted in blocking solution and incubated with the
membranes for 1 h. Excess primary antibody was removed
by washing the membranes three times in PBS-T. The blots
were then incubated in peroxidase-conjugated, secondary an-
tibody diluted in PBS-T for 1 h and subsequently washed
three times in PBS-T. Immunoreactive proteins were de-
tected by ECL. In some experiments, membranes were re-
probed after stripping in 0.1 MTris-HC1 (pH 8.0), 2% SDS,
and 100 mM /3-mercaptoethanol for 30 mm at 52°C.The
blots were rinsed twice in PBS-T and processed as above
with a different primary antibody. Autoluminograms shown
are representative of two to four independent experiments.
Quantitative analysis of autoluminograms was performed by
computer-assisted imaging densitometry (MCID; Imaging
Research, St. Catharines, Ontario, Canada).
Measurement of phosphoinositide turnover
Confluent dishes of SH-SY5Y cells were prelabeled for
48—72 h in DMEM/FCS containing 10 /2Ci/ml [
3H]inositol.
Following a 10-mm pretreatme t with either wortmannin or
LY-294002, cells were treated with agonist for an additional
10 mm, and the accumulation of radiolabeled inositol phos-
phates was determined as described previously (Thompson
and Fisher, 1990).
Phospholipid labeling from 32P,
SH-SY5Y cells plated in 35-mm-diameter wells were in-
cubated at 37°Cin 1 ml of phosphate-free treatment buffer
containing —~20/2Ci/ml 32P, for 2 h. The labeling solution
was aspirated, and unincorporated 32P, was removed by
washing with the same buffer. The cells were then preincu-
bated at 37°Cfor 10 mm with vehicle (0.2% dimethyl sulfox-
ide), 10 jiM wortmannin, or 100 jiM LY-294002, followed
by a further 10-mm incubation with either vehicle or 1 mM
Oxo-M. Reactions were terminated by rapid aspiration of
the treatment solution followed by addition of 0.5 ml of ice-
cold 5% trichloroacetic acid (TCA). Cells were scraped into
the TCA, transferred to glass tubes with an additional 1 ml
of 5% TCA, and allowed to precipitate on ice for I h. Pellets
were obtained by low-speed centrifugation at 4°C and
washed once with 2 ml of ice-cold distilled water, and the
final TCA pellet was resuspended in 0.5 ml of water. Lipids
were extracted from the pellets with acidified chloroform—
methanol as previously described (Fisher and Agranoff,
1980). Phospholipids were then separated on oxalate-im-
pregnated TLC plates and quantified according to a pre-
viously published method (Fisher et al., 1984).
Other measurements
P1 3-kinase activity immunoprecipitated from lysates of
SH-SY5Y cells was assayed as previously described by La-
vie and Agranoff (1996). [3HI NMS binding to intact SH-
SY5Y cells was measured as previously described (Sb-
wiejko et al., 1996). Tn vitro ADP-ribosylation of Rho pro-
teins in SH-SY5Y lysates by recombinant C3 exoenzyme
was performed essentially as described by Yamamoto et a!.
(1993).
Data analysis
Results shown represent the mean ±SEM values for the
number (n) of independent experiments performed. Statisti-
cal differences between the means of unpaired and paired
sets of data were evaluated using Student’s two-tailed t tests.
RESULTS
Agonist occupancy of mAChRs increases the
tyrosine phosphorylation of FAK and paxillin
In preliminary experiments, anti-phosphotyrosine
immunoblots of cell lysates from Oxo-M-stimulated
SH-SY5Y neuroblastoma cells demonstrated the atro-
pine-sensitive tyrosine phosphorylation of 68- and
125-kDa proteins that comigrated with paxillin and
FAK, respectively. To confirm the identity of these
tyrosine-phosphorylated proteins, FAK and paxillin
were immunoprecipitated from control and agonist-
treated SH-SY5Y cell lysates. SH-SY5Y cells treated
for 10 mm with 1 mM Oxo-M showed a 23 ±6-fold
increase (n = 9) in the tyrosine phosphorylation of
FAK (Fig. 1A, upper panel), and a corresponding 6
±1-fold increase (n = 4) in the tyrosine phosphoryla-
tjon of paxillin (Fig. 1 B, upper panel). Reprobing of
these blots for the precipitated proteins demonstrated
equivalent immunoprecipitation efficiencies in the ab-
sence or presence of agonist (Fig. 1A and B, lower
panels). The agonist-stimulated tyrosine phosphoryla-
tion of FAK and paxillin was mediated via mAChRs,
because a 10-mm pretreatment with 10
1uM atropine
resulted in complete inhibition (Fig. 1A and B, upper
panels, respectively). Similar results were also ob-
served for SH-SY5Y cells that had been differentiated
in the presence of retinoic acid for 6 days before addi-
tion of agonist (Fig. 1C and D). Addition of a 1 mM
concentration of a partial muscarinic agonist, pibocar-
pine, also resulted in an increased tyrosine phospho-
rylation of FAK but of a lesser magnitude than that
observed for Oxo-M (41 ± ll%,n = 4,p <0.05).
The time course and dose—response relationships
for the Oxo-M-stimulated tyrosine phosphorylation of
FAK were also determined. The tyrosine phosphoryla-
tion of FAK was half-maximal following a 2-mm ex-
J. Neurochem., Vol. 70, No. 3, 1998
mAChR AND FAK PHOSPHORYLATION 943
addition stimulated the tyrosine phosphorylation of
FAK with an EC50 value of ‘= 10 jiM. In all subsequent
experiments, the tyrosine phosphorylation of FAK and
paxillin was assessed in undifferentiated SH-SY5Y
cells treated with 1 mM Oxo-M for 10 mm.
FIG. 1. Oxo-M stimulates the atropine-sensitive tyrosine phos-
phorylation of FAK and paxillin in SH-SY5Y neuroblastoma cells.
Confluent cultures of SH-SY5Y cells were pretreated for 10 mm
in either the absence (buffer alone) or presence of 10 jiM atro-
pine before addition of either buffer or Oxo-M (final concentra-
tion, 1 mM) for an additional 10 mm. Following treatment, cells
were scraped into lysis buffer, and supernatants containing 200
jig of protein were immunoprecipitated with 1 jig of either a
polyclonal antibody to FAK (A) or a monoclonal antibody to
paxillin (B) as described in Materials and Methods. Immune
complexes were subjected to SOS-PAGE, transferred to PVDF
membranes, and immunoblotted for either phosphotyrosine
(PTyr; upper panels) or the precipitated protein (lower panels).
The blots in A and B are representative of fourand two indepen-
dent experiments, respectively. The experiment described above
was also performed in SH-SY5Y cells that had been differenti-
ated for 6 days with 10 jiM retinoic acid before addition of Oxo-
M with or without atropine, subsequent immunoprecipitation of
FAK (C) and paxillin (D), and immunoblotting for PTyr.
posure to Oxo-M, was maximal at 20 mm, and returned
to approximately the basal level by 120 mm in the
continued presence of the agonist (Fig. 2). Oxo-M
FIG. 2. Time course of Oxo-M-stimulated tyrosine phosphoryla-
tion of FAK. A: Confluent cultures of SH-SY5Y cells were treated
with 1 mM Oxo-M for various times, and FAK immune complexes
were isolated, subjected to SDS-PAGE, transferred to PVDF,
and immurioblotted for phosphotyrosine as described in the leg-
end to Fig. 1. B: Densitometric analysis of Oxo-M-mediated in-
creases in tyrosine phosphorylation of FAK obtained from three
independent experiments.
Oxo-M-stimulated tyrosine phosphorylation of
FAK and paxillin is independent of cell
attachment
Previous reports have demonstrated that the coordi-
nated tyrosine phosphorylation of FAK and paxillin
can be mediated through interaction of cell surface
integrins with ECM proteins (Burridge et a!., 1992).
Because the present experiments were conducted on
SH-SY5Y cells grown on uncoated plastic, the poten-
tial for significant involvement of integrmn—ECM inter-
actions was minimal. However, we could not exclude
the possibility that SH-SY5Y cells may secrete some
ECM components in response to agonist stimulation
that could interact with cell surface integrins and sub-
sequently elicit the tyrosine phosphorylation of FAK
and paxillin via an integrin clustering mechanism.
Therefore, the ability of Oxo-M to stimulate the tyro-
sine phosphorylation of FAK and paxillin in SH-SY5Y
cells maintained in suspension was assessed. Detached
SH-SY5Y cells responded to the addition of Oxo-M
with increases in the tyrosine phosphorylation of FAK
(Fig. 3A) and paxillin (Fig. 3B) that were similar in
magnitude to those observed for attached cells (see
Fig. lA and 1B). These results suggest that the
mAChR-mediated tyrosine phosphorylation of FAK
and paxillin is independent of mntegrin—ECM interac-
tions and cell attachment.
Production of phosphoinositide-derived second
messengers is not required for agonist-stimulated
FAK phosphorylation
Activation of mAChRs in SH-SY5Y cells results in
the formation of both sn-i ,2-diacylglycerol (DAG)
and inositol 1,4,5-trisphosphate (1P3), which subse-
quently activate protein kinase C (PKC) and initiate
FIG. 3. Oxo-M induces the tyrosine phosphorylation of FAK and
paxillin in SH-SY5Y cells maintained in suspension. Confluent
flasks of SH-SY5Y cells were detached in D~solution, resus-
pended in buffer with or without Oxo-M (final concentration, 1
mM), and incubated in a shaking water bath at 37°Cfor 10 mm.
Following treatment, FAK (A) or paxillin (B) immune complexes
were isolated, subiected to SOS-PAGE, transferred to PVDF,
and immunoblotted for phosphotyrosine as described in the leg-
end to Fig. 1. The blots in A and B are representative of four
and two independent experiments, respectively.
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the mobilization of intracellular Ca2~,respectively.Therefore, the role, if any, that these second messen-
gers play in the mediation of the Oxo-M-stimulated
tyrosine phosphorylation of FAK was next investi-
gated.
Two approaches were used to inhibit the activation
of PKC. First, SH-SY5Y cells were pretreated for 30
mm with a 1 jiM concentration of the cell-permeant
PKC inhibitor Ro 31-8220 before Oxo-M addition. Ro
31-8220 pretreatment failed to attenuate the Oxo-M-
stimulated tyrosine phosphorylation of either FAK
(Fig. 4A) or paxillin (data not shown). Second, PKC
was down-regulated by preincubating SH-SY5Y cells
for 18 h with a 1 jiMconcentration of a tumor-promot-
ing phorbol ester, PMA, before a 10-mm incubation
with either 1 mM Oxo-M or 100 nMPMA. In vehicle-
pretreated cells, both Oxo-M and PMA stimulated the
phosphorylation of FAK (Fig. 4B). Thus, PKC activa-
tion alone is capable of eliciting FAK phosphorylation
in SH-SY5Y cells. When cells were pretreated for 18
h with 1 jiM PMA to down-regulate PKC, the basal
level of tyrosine phosphorylation of FAK was in-
creased. Under these conditions, a subsequent acute
exposure to PMA did not increase the phosphorylation
of FAK above this basal level (Fig. 4B). In contrast,
chronic pretreatment of cells with PMA did not impair
FIG. 4. Muscarinic receptor-mediated phosphorylation of FAK
does not require PKC activity or the release ofCa2~from intracel-
lular stores. A: Confluent cultures of SH-SY5Y cells were pre-
treated for 30 mm with either vehicle or a 1 jiM concentration
of the PKC inhibitor Ro 31-8220 (Ro31) before addition of either
buffer or Oxo-M (final concentration, 1 mM) for an additional 10
mm. Following treatment, FAK immune complexes were isolated,
subjected to SOS-PAGE, transferred to PVDF, and immunoblot-
ted for phosphotyrosine as described in the legend to Fig. 1. B:
PKC was down-regulated by an 18-h preincubation with 1 jiM
PMA, and cells were subsequently incubated in the presence of
vehicle, 1 mM Oxo-M, or 100 nM PMA for 10 mi FAK immune
complexes were immunoblotted for phosphotyrosine. C: Con-
fluent cultures of SH-SY5Y cells were pretreated for 30 mm with
either vehicle or 1 jiM thapsigargin (Thaps) before addition of
either buffer or Oxo-M (final concentration, 1 mM) for an addi-
tional 10 mm. Following treatment, FAK immune complexes were
immunoblotted for phosphotyrosmne. The blots in A and C are
each representative of three independent experiments. The blot
in B is representative of two independent experiments.
the ability of Oxo-M to enhance the phosphorylation
of FAK (Fig. 4B). These findings suggest that DAG
activation of PKC is not involved in mediating the
Oxo-M-stimulated tyrosine phosphorylation of FAK.
The potential role of IPrsensitive calcium release
in mediating the tyrosine phosphorylation of FAK and
paxillin following mAChR activation was also as-
sessed. We have previously shown that pretreatment
of SH-SY5Y cells for 30 mm with 1 jiM thapsigargin
totally abolishes the TP
3-mediated increase in intracel-
lular calcium concentration stimulated by addition of
Oxo-M (Slowiejko et al., 1994). In contrast, thapsigar-
gin pretreatment did not inhibit the Oxo-M-stimulated
tyrosine phosphorylation of either FAK (Fig. 4C) or
paxillin (data not shown). Furthermore, no reduction
in the magnitude of Oxo-M-induced phosphorylation
of FAK was observed when SH-SY5Y cells were
treated in a modified buffer that lacked calcium but
contained 1 mM NiC12 [conditions that have pre-
viously been shown to block the plateau phase of 1P3
production and capacitative calcium entry (Wojcikie-
wicz et al., 1994)1. These results suggest that 1P3-
sensitive calcium release and subsequent capacitative
calcium entry are not involved in mediating the Oxo-
M-induced tyrosine phosphorylation of FAK and paxi-
llin.
In addition to DAGand IF3, we also investigated the
potential involvement of two other phosphoinositide-
specific phospholipase C (PlC) -derived second mes-
sengers [lysophosphatidic acid (LPA) and phospha-
tidic acid (PA)] in mediating the agonist-stimulated
tyrosine phosphorylation of FAK. LPA has previously
been shown to stimulate FAK phosphorylation in fi-
broblasts (Seufferlein and Rozengurt, 1994b), and
both of these lipids elicit an increase in the tyrosine
phosphorylation of FAK when added to SH-SY5Y
neuroblastoma cells (data not shown). However, nei-
ther the addition of two inhibitors of phospholipase A2
(AACOCF3 and quinacrine) nor inclusion of I -oleoyl-
2-acetyl-sn-glycerol (a competitive substrate for DAG
lçinase) had any significant effect on the magnitude of
Oxo-M-induced tyrosine phosphorylation of FAK.
Role of the cytoskeleton and Rho in mAChR-
mediated FAK and paxillin tyrosine
phosphorylation
Previous studies have demonstrated that the coinci-
dent tyrosine phosphorylation of FAK and paxillin me-
diated by multiple agonists is dependent on the integ-
rity of the cellular actin microfilament network (Seuf-
ferlein and Rozengurt, 1994a,b; Flinn and Ridley,
1996). In SH-SY5Y cells, a 30-mm pretreatment with
1 jiM cytochalasin D (a compound that selectively
disrupts actin microfilaments) completely abolished
the Oxo-M-stimulated tyrosine phosphorylation of
both FAK (Fig. SA) and paxillin (Fig. SB). Cytocha-
lasin D was also effective at blocking the agonist-
stimulated phosphorylation of FAK in SH-SY5Y cells
maintained in suspension (data not shown). In con-
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FIG. 5. Cytochalasin 0 (Cyto 0) pretreatment inhibits the Oxo-
M-stimulated tyrosmne phosphorylation of FAK and paxillin. Con-
fluent cultures of SH-SY5Y cells were pretreated for 30 mm with
either vehicle or 1 jiM Cyto 0 before addition of either buffer or
Oxo-M (final concentration, 1 mM) for an additional 10 mm.
Following treatment, FAK (A) or paxillmn (B) immune complexes
were isolated, subjected to SDS-PAGE, transferred to PVDF,
and immunoblotted for phosphotyrosine (PTyr) as described in
the legend to Fig. 1. The blots in A and B are representative of
three and two independent experiments, respectively. C: SH-
SY5Y cells were pretreated for 30 mm with either vehicle or 10
jiM Cyto 0 before agonist addition. Cell lysates were subjected
to SOS-PAGE and immunoblotted with an antibody to the active
forms of ERK1 and ERK2.
trast, cytochalasin D pretreatment had no effect either
on the mAChR-mediated activation of ERK1 and
ERK2 (Fig. 5C) or on agonist-induced mAChR se-
questration monitored by a loss of [3HJNMS bindingsites (an —~40%loss in control cells vs. a 45% loss in
cytochalasin D-pretreated cells).
The agonist-stimulated tyrosine phosphorylation of
FAK and paxillin was also significantly attenuated
when SH-SY5Y cells were preincubated for 24 h with
10 jiM mevastatin. Mevastatin is an inhibitor of hydro-
xymethylglutaryl-CoA reductase, which has been
shown to destabilize actin microfilaments via blockade
of synthesis of mevalonate, a precursor required for
the isoprenylation of low-molecular-weight G proteins
involved in cytoskeletal regulation (Bokoch and Pross-
nitz, 1992; Fenton et a!., 1992; Bifulco et a!., 1993).
Mevastatin pretreatment significantly inhibited the
Oxo-M-stimulated tyrosine phosphorylation of both
FAK (Fig. 6A) and paxillin (Fig. 6B). Mevastatin also
induced marked morphological changes characterized
primarily by cellular rounding. All of these effects
were blocked to a significant degree if cells were prein-
cubated with mevastatin in the presence of 1 mM me-
valonate (Fig. 6). Pretreatment with mevalonate alone
did notalter the basal or agonist-stimulated phosphory-
lation of FAK or paxillin (data not shown).
Although recent findings have demonstrated that the
low-molecular-weight G protein Rho may play a role
in mediation of the tyrosine phosphorylation of FAK
in fibroblasts (Rankin et al., 1994; Flinn and Ridley,
1996), no such evidence was obtained for SH-SY5Y
cells. Thus, a 48-h preincubation of SH-SY5Y cells
with 12.5 jig/rn! C3 exoenzyrne (a protein isolated
from Clostridium botulinum that selectively ADP-ribo-
sylates and inactivatesRho proteins) had no significant
FIG. 6. Mevastatin (MST) pretreatment inhibits the muscarinic
receptor-mediated tyrosine phosphorylation of FAK and paxillmn:
attenuation of the inhibitory effects of MSTby inclusion of meval-
onate (MEV). Confluent cultures of SH-SY5Y cells were pre-
treated for 24 h with either vehicle or 10 jiM MSTwith or without
1 mM MEV before addition of either buffer or Oxo-M (final con-
centration, 1 mM) for 10 mm. Following agonist exposure, FAK
(A) or paxillin (B) immune complexes were isolated, subjected
to SOS-PAGE, transferred to PVDF, and immunoblotted for
phosphotyrosine as described in the legend to Fig. 1. The blots
in A and B are representative of three and two independent
experiments, respectively.
effect on the Oxo-M-stimulated tyrosine phosphoryla-
tion of FAK (Fig. 7). Subsequent in vitro measure-
ments of ADP-ribosylation of Rho proteins in lysates
from C3 exoenzyme-pretreated SH-SY5Y cells re-
vealed an ~=35% decrease in 32P incorporation com-
pared with vehicle-pretreated cells.
Wortmannin and LY-294002 attenuate the
agonist-stimulated tyrosine phosphorylation of
FAK and paxillin and selectively decrease 32P
labeling of PI(4)P
Phosphoinositides may play a key role in the mainte-
nance of the cytoskeleton (Lassing and Lmndberg,
1985; Yu et a!., 1990; Fukami et a!., 1992; Hartwig
et al., 1995). Given that an intact cytoskeleton is a
prerequisite for the agonist-stimulated tyrosine phos-
phorylation of FAK and paxillin, a direct role for the
inositol lipids in these signaling events was investi-
gatedby examining the effectsof two structurally unre-
lated inhibitors of phosphoinositide synthesis. Inclu-
sion of low concentrations of either wortmannin
( 100 nM) or LY-294002 ( 10 jiM), conditions un-
der which P1 3-kinase activity is markedly inhibited
in SH-SY5Y cells (>95% inhibition with 100 nM
FIG. 7. C3 exoenzyme (C3 Exo) pretreatment fails to inhibit
Oxo-M-induced FAK phosphorylation. Confluent cultures of SH-
SY5Y cells were premncubated for 48 h with either vehicle or 12.5
jig/mi C3 Exo in DMEM containing 10% FCS before a 10-mm
exposure to 1 mM Oxo-M. Following agonist treatment, FAK
immune complexes were isolated, subjected to SOS-PAGE,
transferred to PVDF, and immunoblotted for phosphotyrosine as
described in the legend to Fig. 1. The blot shown is representa-
tive of three independent experiments.
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wortmannin and >60% inhibition with 10 jiM LY-
294002), had no effect on the agonist-stimulated tyro-
sine phosphorylation of either FAK or paxillin. How-
ever, pretreatment of SH-SY5Y cells with higher con-
centrations of either inhibitor, conditions under which
PT 4-kinase activity is reported to be inhibited (Nakani-
shi et al., 1995; Downing et al., 1996; Meyers and
Cantley, 1997), resulted in complete inhibition of the
tyrosine phosphorylation of FAK (IC50 values forwort-
rnannin and LY-294002, 478 nM and 23 jiM, respec-
tively; Figs. 8A and B and 9A and B). In parallel
experiments, both wortmannin and LY-294002 also
inhibited the tyrosine phosphorylation of paxillin with
dose—inhibition relationships similar to those observed
for FAK (Figs. 8C and 9C).
Consistent with the ability of these agents to inhibit
P1 4-kinase activity, pretreatment of SH-SY5Y cells
with either 10 jiM wortmannin or 100 jiM LY-294002
resulted in a selective decrease in the basal
32P labeling
of PI(4)P by 79 ±2 and 60 ±4%, respectively (n
= 3; Fig. 10). Neither inhibitor had any significant
effect on the basal labeling of PA, P1, or PT 4,5-bis-
phosphate [P1(4,5) P
2 1. Following addition of Oxo-M
to
32P-prelabeled cells, there was a marked increase in
[32PI PA and [32P11 P1 labeling, whereas the radioactiv-
ity incorporated into PI(4)P and PI(4,5)P
2 was de-
FIG. 8. Wortmannin (Wt) pretreatment inhibits the Oxo-M-stim-
ulated tyrosine phosphorylation of FAK and paxillin. Confluent
cultures of SH-SY5Y cells were pretreated for 10 mm with either
vehicle (veh; 0.2% dimethyl sulfoxide) or Wt at the indicated
concentrations before addition of Oxo-M (final concentration, 1
mM) for an additional 10 mm. Following treatment, FAK (A) or
paxillmn (C) immune complexes were isolated, subjected to SDS-
PAGE, transferred to PVDF, and immunoblotted for phosphoty-
rosine as described in the legend to Fig. 1. The blots in A and
C are representative of three and two independent experiments,
respectively. B: Densitometric analysis ofthe Oxo-M-stimulated
tyrosine phosphorylation of FAK obtained from three indepen-
dent experiments.
FIG. 9. LY-294002 (LY) pretreatment attenuates the Oxo-M-
induced tyrosine phosphorylation of FAK and paxillin. Confluent
cultures of SH-SY5Y cells were pretreated for 10 mm with the
indicated concentrations of LY before addition of Oxo-M (final
concentration, 1 mM) for an additional 10 mm. Following treat-
ment, FAK (A) or paxillmn (C) immune complexes were isolated,
subjected to SDS-PAGE, transferred to PVDF, and immunoblot-
ted for phosphotyrosine as described in the legend to Fig. 1. The
blots in A and C are representative of three and two independent
experiments, respectively. B: Densitometric analysis of the Oxo-
M-stimulated tyrosine phosphorylation of FAK obtained from
three independent experiments.
creased (Fig. 10). Preincubation of
32P-labeled cells
with either wortmannin or LY-294002 substantially
reduced the agonist-mediated increases in the labeling
of PA and PT and resulted in further decreases in the
labeling of PI(4)P and PI(4,5)P
2 (Fig. 10). As a
consequence of their ability to block the resynthesis
of PI(4)P [and PI(4,5)P2], both wortmannin and LY-
294002 were shown to inhibit mAChR-stimulated
phosphoinositide hydrolysis, as monitored by the pro-
duction of
3H-inositol pho phates from [3H]inositol-
prelabeled cells, with IC
50 values of 537 nM and 32
jiM, respectively.
DISCUSSION
In this study, we demonstrate that agonist occupancy
of m3 mAChRs in SH-SY5Y neuroblastoma cells re-
sults in an increased tyrosine phosphorylation of FAK
and paxillin, two proteins that have recently been im-
plicated in a signal transduction pathway linked to neu-
rite outgrowth (Bianchi et a!., 1995; Maroney et a!.,
1995; Leventhal and Feldman, 1996; Leventhal et al.,
1997). Although two previous studies have reported
that stimulation of mAChRs transfected into either fi-
broblasts (Gutkind and Robbins, 1992) or Chinese
hamster ovary cells (Savage et a!., 1995) can elicit an
J. Neurochem., Vol. 70, No. 3, 1998
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FIG. 10. Wortmannin (Wt) and LY-294002 (LY) selectively de-
crease the incorporation of 32P, into Pl(4)P (PIP). Confluent cul-tures of SH-SY5Y cells were prelabeled with 32P for 2 h. Unincor-
porated label was washed away, and the cells were pretreated
(Pre) for 10 mm with vehicle (Veh; 0.2% dimethyl sulfoxide), 10
jiM Wt (A), or 100 jiM LY (B) before treatment (Treat) with either
veh or Oxo-M (final concentration, 1 mM) for an additional 10
mm. Reactions were terminated by addition of TCA, lipids were
extracted and separated, and radioactivity was quantified as
described in Materials and Methods. Data are mean ±SEM
(bars) values for three independent experiments with each inhibi-
tor and are expressed as percentages of the veh/veh control
value. PIP
2, Pl(4,5)P2.
increase in the tyrosine phosphorylation of FAK, the
present study is the first demonstration of such for an
endogenous mAChR in a neural cell line. In addition,
the mAChR-mediated tyrosine phosphorylation of
FAK and paxillin was observed in both undifferenti-
ated and retinoic acid-differentiated SH-SY5Y cells.
The mAChR-mediated tyrosine phosphorylation of
FAK and paxillin in SH-SY5Y cells is independent of
integrin interactions with the ECM, as phosphorylation
of both proteins could be readily demonstrated when
cells were maintained in suspension (Fig. 3). This
observation ms in contrast to previous reports demon-
strating that, following activation of integrin receptors,
detachment of cells from the ECM results in the rapid
dephosphorylation of FAK and paxillin (Kornberg et
al., 1992; Leventhal and Feldman, 1996). However,
our results are in agreement with a recent study in
which an enhanced phosphorylation of FAK was ob-
served in response to addition of either LPA or active
Rho protein to suspensions of (scrape-loaded) Swiss
3T3 fibroblasts (Flinn and Ridley, 1996). Thus, it ap-
pears that cell attachment is not invariably a prerequi-
site for the increased tyrosine phosphorylation of FAK
and paxillin and that the signaling events that initiate
this phosphorylation cascade following mAChR acti-
vation in SH-SY5Y cells can occur in an environment
devoid of focal contacts with the ECM.
There is some uncertainty regarding the role that
phosphoinositide-derived second messengers, e.g., 1P3
and DAG, may play in mediating the enhanced tyrosine
phosphorylation of FAK following agonist occupancy
of receptors coupled to PlC activation. For example,
whereas evidence suggesting the involvement of either
PKC or Ca
2~has been obtain d (Leeb-Lundberg t
al., 1994; Savage et al., 1995), the results from other
studies are inconsistent with these observations (Sin-
net-Smith et a!., 1993; Seuffer!ein and Rozengurt,
1994b). Our results indicate that, in SH-SY5Y cells,
the production of phosphoinositide-derived second
messengers is not a prerequisite for the enhanced tyro-
sine phosphorylation of FAK elicited by mAChR stim-
ulation. The evidence for this conclusion is threefold.
First, neither the inhibition of PKC by Ro 31-8220 nor
its depletion from cells by chronic PMA pretreatment
decreased the extent of tyrosine phosphorylation of
FAK in response to mAChR activation. Second, nei-
ther depletion of intracellular Ca2~stores with thapsi-
gargin nor blockade of Ca2~entry withNi 2±attenuated
the phosphorylation of FAK. Third, no evidence was
obtained for the involvement of other putative down-
streammessenger molecules such as PA or LPA, given
that inhibitors of DAG kinase and phospholipase A
2
had no effect on the agonist-stimulated phosphoryla-
tion of FAK. The absence of a requirement for PKC
activation in the mAChR-mediated tyrosine phosphor-
ylation of FAK is in contrast to the previously demon-
strated role for PKC in the stimulation of the mitogen-
activated protein kinase (MAPK) pathway elicited by
activation of the same receptors in these cells (Of-
fermanns et al., 1993). This observation is of signifi-
cance because the tyrosine phosphorylation of FAK
has been linked to activation of the Ras /MAPK cas-
cade via the association of FAK with the adapter pro-
tein GRB-2 (Schlaepfer eta!., 1994). However, in SH-
SY5Y cells, the mAChR-mediated activation of FAK
and that of MAPK appear to be parallel, but indepen-
dent, events.
A characteristic feature of the tyrosine phosphoryla-
tion of FAK elicited in responseto addition of a diverse
range of stimuli is its susceptibility to addition of cyto-
chalasin D with the attendant disruption of the actin
cytoskeleton. The increases in the tyrosine phosphory-
lation of FAK and paxillin resulting from mAChR acti-
vation in SH-SY5Y cells were similarly prevented by
inclusion of cytochalasin D (Fig. 5). Cytochalasin D
sensitivity was also observed for mAChR-mediated in-
creases in the tyrosine phosphorylation of FAK e!icited
in SH-SY5Y cells maintained in suspension (data not
shown). In contrast, other consequences of mAChR
activation in these cells, such as receptor internaliza-
tion and MAPK activation, were unaffected by cyto-
chalasin D. The conclusion that an intact actin cy-
toskeleton is required for FAK phosphorylation was
further substantiated by the observation that pretreat-
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ment of the cells with mevastatin, an agent known to
destabilize actin microfilaments, also attenuated the
agonist-stimulated tyrosine phosphorylation of FAK
and paxillin. The inhibitory effects of mevastatin could
largely be prevented by inclusion of mevalonate, a
precursor molecule required for the isoprenylation of
various proteins, including some low-molecular-
weight G proteins implicated in the regulation of the
cytoskeleton. In this context, recent studies indicate
that in fibroblasts, the low-molecular-weight G protein
p2lRho may play a pivotal role in mediating the tyro-
sine phosphorylation of FAK and paxillin (Rankin et
al., 1994; Flinn and Ridley, 1996). This may not be
the case for the mAChR-mediated tyrosine phosphory-
!ation of FAK in SH-SY5Y neuroblastoma cells be-
cause pretreatment with C3 exoenzyme failed to pre-
vent the agonist-induced increase in the tyrosine phos-
phorylation of FAK. However, as only a partial ADP-
ribosylation of Rho proteins in SH-SY5Y cells was
observed, any such conclusion must remain tentative.
Recently it has been shown that mAChR-mediated ac-
tin stress fiber formation in transfected Chinese ham-
ster ovary cells is also insensitive to C3 exoenzyme
(Williams et a!., 1996). Taken collectively, these re-
sults suggest that if a low-molecular-weight G protein
is involved in the mAChR-mediated alterations of the
cytoskeleton and signaling events that lead to the tyro-
sine phosphorylation of FAK, it may not invariably
be Rho.
The actin cytoskeleton is known to be markedly
influenced by phosphoinositides. For example, these
lipids modulate the functions of several actin binding
proteins (Lassing and Lindberg, 1985; Yu et a!., 1990;
Fukami et a!., 1992) and can induce actin filament
uncapping, thereby facilitating actin polymerization
(Hartwig et al., 1995). A major finding to emanate
from the present study is that the synthesis of poly-
phosphoinositides, specifically that of P1(4)F, is re-
quired for the increased tyrosine phosphorylation of
FAK and paxillin in response to mAChR activation.
Pretreatment of SH-SY5Y cells with concentrations
of either wortmannin or LY-294002 that inhibit the
synthesis of P1(4)P resulted in a marked attenuation
of the phosphorylation of FAK and paxillin (see Figs.
8 and 9). In contrast, no inhibition of phosphorylation
was observed at concentrations of these inhibitors
( 100 nM for wortmannin and 10 jiM for LY-
294002) that are more specific for inhibition of PT 3-
kinase (Yano et al., 1995). In this context, it should
be noted that inclusion of either 30 nM wortmannin
or 10 jiM LY-294002 has been reported to inhibit the
enhanced tyrosine phosphorylation of FAK in platelet-
derived growth factor-stimulated fibroblasts by 65—
100%, a result consistent with the involvement of PT
3-kinase (Rankin et al., 1996). However, in the same
study, these inhibitor concentrations were without ef-
fect on the tyrosine phosphorylation of FAK induced
by activation of bombesin receptors (which, like
mAChRs, couple to PlC via Gq). Although both wort-
mannin and LY-294002 have also been demonstrated
to inhibit activity of myosin light chain kinase
(MLCK) (Yano et al., 1995), a key enzyme involved
in the regulation of actin/myosin interactions and cell
contractility (see Burridge and Chrzanowska-Wod-
nicka, 1996), a role for this enzyme in the mAChR-
mediated tyrosine phosphorylation of FAK and paxil-
lin appears unlikely for three reasons. First, although
MLCK is a Ca2~-dependentenzyme, there is no such
Ca2~requirement for the phosphorylation of FAK and
paxillin (see Fig. 4C). Second, pretreatment of SH-
SY5Y cells with 10 jiM ML-7, a known inhibitor of
MLCK, was without effect on the phosphorylation of
FAK (data not shown). Third, whereas pretreatment
of SH-SY5Y cells with 100 jiM LY-294002 resulted
in a >95% inhibition of the tyrosine phosphorylation
of FAK and paxillin, only a small inhibitory effect on
MLCK is observed at this concentration (Yano et al.,
1995). An additional possibility, i.e., that wortmannin
directly inhibits the autokinase activity of FAK, also
appears unlikely given that other tyrosine kinases, e.g.,
Src or MEK, are not inhibited by wortmannin (Brunn
et al., 1996). In agreement with their reported ability
to inhibit PT 4-kinase activity (Nakanishi et al., 1995;
Downing et a!., 1996; Meyers and Cantley, 1997),
addition of either wortmannin or LY-294002 to SH-
SY5Y cells resulted in a selective inhibition of P1(4) P
synthesis, as demonstrated by a decreased 32P labeling
(Fig. 10). In the presence of Oxo-M, which when
added alone reduces PI(4)P and PT(4,5)P
2 labeling,
the inclusion of either inhibitor resulted in a further
reduction in polyphosphoinositide labeling. As antici-
pated, inhibition of polyphosphomnositide synthesis by
wortmannin or LY-294002 resulted in a marked reduc-
tion in the extent of mAChR-stimulated inositol lipid
hydrolysis, as monitored by the release of radiolabeled
inositol phosphates. From dose—inhibition studies, the
latter parameter was found to be highly correlated with
the extent of inhibition of the tyrosine phosphorylation
qf FAK for both wortmannin (r = 0.995, p < 0.001)
and LY-294002 (r = 0.976, p <0.01). Taken collec-
tively, these results suggest that wortmannin and LY-
294002 deplete the cellular content of phosphoinosi-
tides. A consequence of this may be that the normal
maintenance of the actin cytoskeleton by these lipids is
compromised, thereby depriving FAK of the required
environment in which it can autophosphorylate and
become fully activated.
In summary, the present results indicate that on ago-
nist occupancy of mAChRs in SH-SY5Y cells, there
is a marked increase in the tyrosine phosphorylation of
FAK and paxillin. Increases in phosphorylation occur
independently of the production of phosphoinositide-
derived second messengers but require the continuous
synthesis of inositol lipids. The latter may reflect a
role for these lipids in the maintenance of an intact
actin cytoskeleton, which is a prerequisite for the in-
creased tyrosine phosphorylation of FAK and paxillin.
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